These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30076385)

  • 1. S100 proteins in rheumatic diseases.
    Austermann J; Spiekermann C; Roth J
    Nat Rev Rheumatol; 2018 Sep; 14(9):528-541. PubMed ID: 30076385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alarmins of the S100-Family in Juvenile Autoimmune and Auto-Inflammatory Diseases.
    Holzinger D; Tenbrock K; Roth J
    Front Immunol; 2019; 10():182. PubMed ID: 30828327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.
    Gabay C; McInnes IB
    Arthritis Res Ther; 2009; 11(3):230. PubMed ID: 19519923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calprotectin in rheumatic diseases.
    Ometto F; Friso L; Astorri D; Botsios C; Raffeiner B; Punzi L; Doria A
    Exp Biol Med (Maywood); 2017 Apr; 242(8):859-873. PubMed ID: 27895095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation.
    Foell D; Frosch M; Sorg C; Roth J
    Clin Chim Acta; 2004 Jun; 344(1-2):37-51. PubMed ID: 15149869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers.
    Kessel C; Holzinger D; Foell D
    Clin Immunol; 2013 Jun; 147(3):229-41. PubMed ID: 23269200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules.
    Foell D; Wittkowski H; Vogl T; Roth J
    J Leukoc Biol; 2007 Jan; 81(1):28-37. PubMed ID: 16943388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of B cells for rheumatic autoimmune diseases.
    Engel P; Gómez-Puerta JA; Ramos-Casals M; Lozano F; Bosch X
    Pharmacol Rev; 2011 Mar; 63(1):127-56. PubMed ID: 21245206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [S100A8, S100A9 and S100A12 proteins in rheumatoid arthritis].
    Baillet A
    Rev Med Interne; 2010 Jun; 31(6):458-61. PubMed ID: 20398973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review: basics of drug development in rheumatology.
    Mina-Osorio P
    Arthritis Rheumatol; 2015 Oct; 67(10):2581-90. PubMed ID: 26138901
    [No Abstract]   [Full Text] [Related]  

  • 11. Pound the alarm: danger signals in rheumatic diseases.
    O'Reilly S
    Clin Sci (Lond); 2015 Mar; 128(5):297-305. PubMed ID: 25394289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments.
    Morozzi G; Fabbroni M; Bellisai F; Pucci G; Galeazzi M
    Ann N Y Acad Sci; 2007 Jun; 1108():398-407. PubMed ID: 17894003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.
    Cope AP; Aderka D; Doherty M; Engelmann H; Gibbons D; Jones AC; Brennan FM; Maini RN; Wallach D; Feldmann M
    Arthritis Rheum; 1992 Oct; 35(10):1160-9. PubMed ID: 1329774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelets in rheumatic diseases: friend or foe?
    Gasparyan AY; Ayvazyan L; Pretorius E; Kitas GD
    Curr Pharm Des; 2014; 20(4):552-66. PubMed ID: 23565634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nrf2 as a therapeutic target for rheumatic diseases.
    Ferrándiz ML; Nacher-Juan J; Alcaraz MJ
    Biochem Pharmacol; 2018 Jun; 152():338-346. PubMed ID: 29660314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate and long-term treatment of rheumatic disease: comment on the article by Kremer.
    Ranganathan P; McLeod HL
    Arthritis Rheum; 2005 Feb; 52(2):670-1; author reply 672. PubMed ID: 15692997
    [No Abstract]   [Full Text] [Related]  

  • 17. Type I interferon in rheumatic diseases.
    Muskardin TLW; Niewold TB
    Nat Rev Rheumatol; 2018 Mar; 14(4):214-228. PubMed ID: 29559718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 19. Heme oxygenase-1 as a potential therapeutic target in rheumatic diseases.
    Liu YT; Lin ZM; He SJ; Zuo JP
    Life Sci; 2019 Feb; 218():205-212. PubMed ID: 30580021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.
    Cronstein BN; Sitkovsky M
    Nat Rev Rheumatol; 2017 Jan; 13(1):41-51. PubMed ID: 27829671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.